ACRV vs FFNW Comparison

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

First Financial Northwest Inc is the holding company. The Bank's business consists predominantly of attracting deposits from the general public, combined with borrowing from the FHLB of Des Moines and raising funds in the wholesale market then utilizing these funds to originate one-to-four family residential, multifamily, commercial real estate, construction/land, business, and consumer loans. The Bank's strategic initiatives seek to diversify its loan portfolio and broaden growth opportunities with its current risk tolerance levels and asset/liability objectives.